Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Nanda HorewegRemi A NoutIna M Jürgenliemk-SchulzLudy C H W LutgensJan J JobsenMarie A D HaverkortJan Willem M MensAnnerie SlotBastiaan G WortmanStephanie M de BoerEllen StellooKaren W Verhoeven-AdemaHein PutterVincent T H B M SmitTjalling BosseCarien L Creutzbergnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
mut EC. The benefit of radiotherapy seems to be limited in MMRd EC. EBRT yields a significantly better locoregional recurrence-free survival than VBT or no adjuvant therapy in p53abn EC. VBT is the treatment of choice for NSMP EC as it is as effective as EBRT and significantly better than no adjuvant therapy for locoregional tumor control.